x

Search for a clinical trial

* (*) mandatory field

Optima Trial: A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) using standardized Radiofrequency Ablation (RFA) treatment time >= 45 minutes for solitary lesions >= 3 cm to =< 7 cm. - ES

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Ongoing trial
  • Funding body(ies) :
  • CELSION CORPORATION
  • Geographic coverage : Global
  • Sponsor : -
    • Phase : III
Last update: May 2019

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.